Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Retinoid Clear all
Completed Phase 2 Interventional Results available

Podocyte Retinoids

NCT00098020
View directory record Official record
Conditions
Collapsing Glomerulopathy, Glomerulosclerosis, Focal Segmental
Interventions
Isotretinoin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
16 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 18, 2026, 2:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fruit and Vegetable Juice Concentrate Effects on RBP4 and Antioxidant Capacity in Lean and Overweight 6-10 Year Old Boys

NCT00842543
View directory record Official record
Conditions
Obesity
Interventions
Fruit and Vegetable Juice Concentrate (FVJC), Placebo
Dietary Supplement
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
6 Years to 10 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 18, 2026, 2:05 AM EDT
Not listed Phase 4 Interventional

Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects?

NCT01228409
View directory record Official record
Conditions
Psoriasis
Interventions
Acitretin 17.5 mg/day
Drug
Lead sponsor
Frankel, Amylynne, M.D.
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 18, 2026, 2:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Retinoid 9cUAB30 in Preventing Cancer in Healthy Volunteers

NCT01935960
View directory record Official record
Conditions
Healthy Subject
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Retinoid 9cUAB30
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
3
States / cities
Birmingham, Alabama • Iowa City, Iowa • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 23, 2016 · Synced Oct 18, 2026, 2:05 AM EDT
Completed Phase 2 Interventional

A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor

NCT00001509
View directory record Official record
Conditions
Nephroblastoma, Neuroblastoma
Interventions
IFN-alpha with retinoic acid
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 18, 2026, 2:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect Of A Controlled Daily Skin Care Regimen On Retinoic Acid Tolerance

NCT00440024
View directory record Official record
Conditions
Sun-Damaged Skin, Retinoid Intolerance
Interventions
Tazorac, Dove Mild Cleanser, Dove Facial Moisturizer
Drug
Lead sponsor
University of Michigan
Other
Eligibility
40 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 18, 2026, 2:05 AM EDT
Completed Phase 1 Interventional

A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients

NCT00001504
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasm
Interventions
9-cis-Retinoic Acid
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 18, 2026, 2:05 AM EDT
Not listed Phase 2 Interventional

Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia

NCT00675870
View directory record Official record
Conditions
Acute Promyelocytic Leukemia
Interventions
NRX 195183 Soft Gelatin Capsule
Drug
Lead sponsor
NuRx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated May 12, 2008 · Synced Oct 18, 2026, 2:05 AM EDT
Withdrawn Phase 2 Interventional

New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia

NCT00670150
View directory record Official record
Conditions
Acute Promyelocytic Leukemia
Interventions
NRX 195183 (retinoid analogue), Arsenic Trioxide
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Oct 18, 2026, 2:05 AM EDT
Completed Phase 2 Interventional

TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)

NCT00413205
View directory record Official record
Conditions
Emphysema
Interventions
Placebo, RAR Gamma
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
44 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 18, 2026, 2:05 AM EDT
Completed Not applicable Interventional Results available

Photodynamic Therapy With Levulan® +/- Topical Retinoid Pre-Treatment In The Treatment Of Actinic Keratoses

NCT01053000
View directory record Official record
Conditions
ACTINIC KERATOSES
Interventions
Tazorac
Drug
Lead sponsor
Stewart, Roger H., M.D., P.A.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2015 · Synced Oct 18, 2026, 2:05 AM EDT
Completed Not applicable Interventional

UMCC 9609 Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia

NCT00003598
View directory record Official record
Conditions
Cervical Cancer, Precancerous/Nonmalignant Condition
Interventions
tretinoin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
14 Years and older · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 22, 2010 · Synced Oct 18, 2026, 2:05 AM EDT
Completed Phase 3 Interventional

Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

NCT00050973
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
bexarotene
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
Not listed
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • Pasadena, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 18, 2026, 2:05 AM EDT
Terminated Phase 1 Interventional

Phase I Study of CS-7017 and Bexarotene

NCT01504490
View directory record Official record
Conditions
Solid Tumors, Lymphoma, Multiple Myeloma
Interventions
CS-7017 and Bexarotene
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Oct 18, 2026, 2:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of 9cUAB30 in Healthy Participants

NCT00896974
View directory record Official record
Conditions
No Evidence of Disease
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Retinoid 9cUAB30
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Oct 18, 2026, 2:05 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis

NCT00322296
View directory record Official record
Conditions
Parapsoriasis
Interventions
Bexarotene 1% gel
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Oct 18, 2026, 2:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Retinol-induced Dermatitis in Aged Skin

NCT00857610
View directory record Official record
Conditions
Aged Skin, Photoaged Skin
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 60 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 18, 2026, 2:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of a Topical Retinol on Epigenetic Changes and Expression of Certain Genes in the Skin Using Non-invasive Measurements

NCT06658847
View directory record Official record
Conditions
Retinoid, Skin Aging, Epigenomics
Interventions
Night Cream Usage, No Night Cream Usage
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 18, 2026, 2:05 AM EDT
Terminated Phase 1 Interventional Results available

Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer

NCT02876640
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Early Stage Breast Carcinoma, Invasive Breast Carcinoma
Interventions
Biospecimen Collection, Retinoid 9cUAB30, Therapeutic Conventional Surgery
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Birmingham, Alabama • Chicago, Illinois • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 18, 2026, 2:05 AM EDT
Completed Phase 4 Interventional

Comparison of Tazarotene and Minocycline Therapies for Maintenance of Facial Acne Vulgaris

NCT00145106
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene 0.1% gel + placebo capsule, Oral minocycline (100 mg capsule) + vehicle gel, Tazarotene 0.1% gel + oral minocycline (100 mg capsule)
Drug
Lead sponsor
KGL, Inc.
Other
Eligibility
12 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2005 · Synced Oct 18, 2026, 2:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Retinoids on CYP2D6 Activity During Pregnancy

NCT03117660
View directory record Official record
Conditions
CYP2D6 Polymorphism
Interventions
Vitamin A
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 18, 2026, 2:05 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Dose-Finding of Retinoid 9cUAB30 in Healthy Volunteers

NCT01336387
View directory record Official record
Conditions
Healthy, no Evidence of Disease
Interventions
retinoid 9cUAB30, placebo, pharmacological study, laboratory biomarker analysis, cancer prevention
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Oct 18, 2026, 2:05 AM EDT
Withdrawn Phase 2 Interventional

Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens

NCT01275274
View directory record Official record
Conditions
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions
Retinoic acid, Standard of care
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 18, 2026, 2:05 AM EDT
Completed Early Phase 1 Interventional Results available

A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression

NCT00718770
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Bexarotene
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 18, 2026, 2:05 AM EDT